Bafna Pharmaceuticals Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Bafna Pharmaceuticals share price target for 2026 stands at Rs 165 as per analyst consensus, implying approximately 24 percent upside from the current market price of Rs 133.5. Investors tracking the Bafna Pharmaceuticals share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings outlook, key risks, and the bull versus bear case scenarios. This article covers every dimension of the Bafna Pharmaceuticals share price target thesis, updated May 2026.

Click Here – Get Free Investment Predictions

Bafna Pharmaceuticals Company Overview

Bafna Pharmaceuticals (NSE: BAFNAPH) operates in the Pharmaceuticals sector. At CMP Rs 133.5 against a 52 week range of Rs 72.01 to Rs 202.06, the stock offers a potential re-rating opportunity for investors focused on the Bafna Pharmaceuticals share price target of Rs 165. The company’s market capitalisation stands at Rs 391 crore. Tracking the Bafna Pharmaceuticals share price target 2026 requires monitoring FY27 earnings delivery and sector-level demand trends as the primary valuation catalysts.

Parameter	Value
NSE Ticker	BAFNAPH
Sector	Pharmaceuticals
CMP May 2026	Rs 133.5
52 Week High	Rs 202.06
52 Week Low	Rs 72.01
Market Cap	Rs 391 crore
Trailing P/E	33
12M Analyst Target	Rs 165
Bull Case Target	Rs 200
Bear Case Target	Rs 100

Why Is Bafna Pharmaceuticals Share Price Target Set at Rs 165 for 2026

FY27 Earnings Delivery and Revenue Acceleration

FY27 is the pivotal year for the earnings recovery thesis underpinning the Bafna Pharmaceuticals share price target 2026 of Rs 165. Analysts project 15 to 20 percent PAT growth in FY27 as operational leverage and strategic investments begin contributing meaningfully to the top line. Positive Q4 FY26 results paired with forward guidance are the immediate re-rating trigger for the stock to close the gap toward Rs 165.

Structural Sector Tailwinds in Pharmaceuticals

India’s Pharmaceuticals sector is expanding as demand recovers and companies invest in capacity and technology. Bafna Pharmaceuticals’s market position creates a compounding growth runway that supports the analyst consensus of Rs 165. Improving sectoral fundamentals are expected to accelerate earnings momentum through FY27, reinforcing the bull case of Rs 200.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle, which commenced in early 2026, reduces Bafna Pharmaceuticals’s borrowing costs and stimulates demand across its end markets. Lower interest costs improve EBITDA to PAT conversion, directly expanding EPS. Any further rate cuts through FY27 compound this benefit and add upside optionality, strengthening the case for the Bafna Pharmaceuticals share price target of Rs 165.

Union Budget 2026 Policy Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Bafna Pharmaceuticals’s Pharmaceuticals business. These policy tailwinds directly improve the probability of achieving the Rs 165 analyst estimate over the next 12 months.

Improving FII Flows

As macro conditions normalise post the April 2026 US tariff shock, FII flows into quality Indian companies are expected to recover through FY27. Bafna Pharmaceuticals’s valuation relative to sector peers positions it as a potential beneficiary of institutional reallocation, adding support to the Rs 165 price objective.

Check the Univest Screener for live data and real-time fundamentals.

Bafna Pharmaceuticals Share Price Targets Short Term 12 Month and Long Term

Short Term Target 3 to 6 Months

The short term outlook for Bafna Pharmaceuticals is anchored to the 52 week low support zone near Rs 72.01. In the 3 to 6 month timeframe, a recovery toward 10 to 15 percent above current levels is the base case if Q4 FY26 results confirm the earnings recovery trajectory. Any positive operational update could serve as a near-term catalyst toward the Bafna Pharmaceuticals share price target of Rs 165.

12 Month Bafna Pharmaceuticals Share Price Target 2026

The 12 month Bafna Pharmaceuticals share price target 2026 is Rs 165, implying approximately 24 percent upside from CMP Rs 133.5. This base case assumes in-line FY27 earnings delivery, partial normalisation of FII flows, and continued strategic execution. Track the stock’s live data on NSE ticker BAFNAPH.

Long Term Target FY27 to FY28

For investors with a 2 to 3 year horizon, the bull case extends to Rs 200. Full FY27 to FY28 earnings delivery, strategic expansion, and sector re-rating toward higher peer multiples are the conditions required. The long-term thesis rests on Bafna Pharmaceuticals’s market position and its expanding addressable opportunity in the Pharmaceuticals space.

Bull Case and Bear Case for Bafna Pharmaceuticals Share Price Target

Bull Case Bafna Pharmaceuticals Share Price Target Rs 200

The bull case of Rs 200 materialises if FY27 earnings exceed analyst estimates, sector tailwinds accelerate beyond consensus, and FII flows return to quality Indian names. Under this scenario, the stock re-rates toward higher earnings multiples, making Rs 200 achievable within FY27 to FY28.

Bear Case Rs 100

The bear case tests Rs 100 if FY27 earnings guidance disappoints and FII outflows persist. At Rs 100, the stock revisits near the support zone, requiring a full reassessment of the analyst thesis before fresh targets can be assigned.

Scenario	Price Target	Conditions
Bull Case	Rs 200	FY27 earnings beat, sector re-rating, FII inflows, macro normalisation
Base Case Analyst Forecast	Rs 165	In-line FY27 delivery, partial FII recovery, steady execution
Bear Case	Rs 100	FY27 guidance cut, earnings miss, persistent FII outflows

Key Risks to the Bafna Pharmaceuticals Share Price Target 2026

US Tariff Macro Headwind

The 26 percent US reciprocal tariff announced April 2, 2026 created FII outflow pressure and broad market volatility. A re-escalation of trade tensions could delay the re-rating required to reach the Bafna Pharmaceuticals share price target of Rs 165 within the 12 month timeframe.

Valuation and Earnings Miss Risk

If FY27 earnings fall short of consensus, the stock could de-rate toward the bear case of Rs 100. Margin pressure, higher raw material costs, or demand slowdown are the primary triggers for an earnings miss.

Competitive Pressure in Pharmaceuticals

Intensifying competition in the Pharmaceuticals segment could compress margins and slow revenue growth, reducing the probability of reaching Rs 165. Investors should monitor quarterly margin trends as a leading indicator of competitive dynamics.

FII Selling Pressure

Sustained FII outflows from Indian equities, driven by global risk-off sentiment or dollar strength, could weigh on the stock’s trajectory. Any reversal of the FII recovery narrative would reduce upside probability toward Rs 165.

How to Invest in Bafna Pharmaceuticals

Start by researching Bafna Pharmaceuticals’s fundamentals including revenue growth, EBITDA margins, and FY27 earnings guidance. Use the Univest Screener to compare the stock against Pharmaceuticals sector peers and validate the Bafna Pharmaceuticals share price target thesis of Rs 165 before committing capital.

Open a SEBI-registered demat and trading account with a broker offering direct NSE access. Search for ticker BAFNAPH to find the stock’s live price and order book. Consider your entry point relative to the 52 week low of Rs 72.01 and 52 week high of Rs 202.06 to assess risk-reward.

Define your investment horizon before buying. Short term traders should monitor Q4 FY26 results and FY27 quarterly guidance closely. Long term investors focused on the Rs 200 bull case should review annual earnings delivery and sector re-rating triggers each quarter.

Size your position according to your overall portfolio risk tolerance. No single stock should represent an outsized proportion of your portfolio. Diversification across sectors and market caps is a key principle endorsed by SEBI-registered advisors.

Set a stop-loss and target exit strategy aligned with the bull case Rs 200 and bear case Rs 100 scenarios. Revisit your investment thesis quarterly to ensure the fundamental drivers for the Bafna Pharmaceuticals share price target remain intact and no material adverse developments have emerged.

Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals live price and get daily stock recommendations.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

FAQs on Bafna Pharmaceuticals Share Price Target 2026

What is the Bafna Pharmaceuticals share price target for 2026?

Ans. The Bafna Pharmaceuticals share price target for 2026 is Rs 165 as per analyst consensus, implying approximately 24 percent upside from CMP Rs 133.5.

Is Bafna Pharmaceuticals a good buy at CMP Rs 133.5?

Ans. Whether Bafna Pharmaceuticals is a good investment at Rs 133.5 depends on your risk appetite and horizon. Investors should review FY27 earnings guidance and sector tailwinds, and consult a SEBI-registered advisor before committing capital.

What is the 52 week high and low of Bafna Pharmaceuticals?

Ans. The 52 week high of Bafna Pharmaceuticals is Rs 202.06 and the 52 week low is Rs 72.01. The stock trades below its 52 week high, which some investors view as a potential re-entry point.

What are the main risks to the Bafna Pharmaceuticals share price target?

Ans. Key risks to the Bafna Pharmaceuticals share price target of Rs 165 include FY27 earnings disappointment, US tariff-driven FII outflows, competitive pressure in Pharmaceuticals, and valuation de-rating if results miss consensus.

What are the key catalysts for Bafna Pharmaceuticals in 2026?

Ans. Key catalysts include FY27 earnings delivery, RBI rate cut benefits, Pharmaceuticals sector tailwinds, improving FII flows, and Union Budget 2026 policy support that can drive the stock toward the analyst target of Rs 165.

Where can I track Bafna Pharmaceuticals live price and analyst data?

Ans. Track Bafna Pharmaceuticals on NSE ticker BAFNAPH. The Univest Screener provides real-time fundamentals, analyst targets, and portfolio tools for Bafna Pharmaceuticals and all listed Indian stocks.

What is the Bafna Pharmaceuticals share price target for 2027?

Ans. In the bull case, the long-term Bafna Pharmaceuticals share price target extends to Rs 200 through FY27 to FY28, contingent on sustained earnings growth, sector re-rating, and continued strategic execution.

How can I buy Bafna Pharmaceuticals shares?

Ans. Open a demat account with a SEBI-registered broker, search NSE ticker BAFNAPH, and place a buy order. Univest offers research, screener access, and brokerage services to help you invest in Bafna Pharmaceuticals.